What differentiates primary care physicians who predominantly prescribe diuretics for treating mild to moderate hypertension from those who do not? A comparative qualitative study

BMC Family Practice

Volumn 13, Issue , 2012, Pages

  Rochefort, Christian M ^a,b   Morlec, Julia ^a,b   Tamblyn, Robyn M ^a,b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Antihypertensive treatments; Cost effectiveness; Hypertension; Physician; Prescribing behavior; Qualitative study

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIURETIC AGENT;

ARTICLE; CANADA; CLINICAL PRACTICE; COMPARATIVE STUDY; DECISION MAKING; DRUG UTILIZATION; GENERAL PRACTITIONER; HUMAN; HYPERTENSION; INTERVIEW; PRESCRIPTION; PSYCHOLOGICAL ASPECT; QUALITATIVE RESEARCH; STATISTICS;

ANTIHYPERTENSIVE AGENTS; DECISION MAKING; DIURETICS; DRUG PRESCRIPTIONS; DRUG UTILIZATION; HUMANS; HYPERTENSION; INTERVIEWS AS TOPIC; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS, FAMILY; QUALITATIVE RESEARCH; QUEBEC;

EID: 84857498920     PISSN: None     EISSN: 14712296     Source Type: Journal    
DOI: 10.1186/1471-2296-13-9     Document Type: Article

References (48)

1. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense H-W, Joffres M, Kastarinen M, Poulter N, Primatesta P, Rodríguez-Altalejo F, Stegmayr B, Thamm M, Tuomilehto J, Vannuzzo D, Vescio F, JAMA 2003 289 18 2363 2369 10.1001/jama.289.18.2363 12746359 (Pubitemid 37430168)
2. Hypertension: trends in prevalence, incidence and control. Hajjar I, Kotchen JM, Kotchen TA, Annu Rev Public Health 2006 27 465 490 10.1146/annurev.publhealth.27.021405.102132 16533126
3. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ, Hypertension 2008 52 818 827 10.1161/HYPERTENSIONAHA.108.113357 18852389
4. Blood pressure as a cardiac risk factor: prevention and treatment. Kannel WB, JAMA 1996 275 4 1571 1576 8622248 (Pubitemid 26154243)
5. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): case-control study. Yusuf S, Hawken S, unpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, On behalf of the INTERHEART Study investigators, Lancet 2004 364 937 952 10.1016/S0140-6736(04)17018-9 15364185 (Pubitemid 39208455)
6. Trends in antihypertensive drug prescriptions and physician visits in Canada between 1996 and 2006. Hemmelgarn BR, Chen G, Walker R, McAlister FA, Quan H, Tu K, Khan N, Campbell N, Can J Cardiol 2008 24 6 507 512 10.1016/S0828-282X(08)70627-5 18548150
7. Identification of factors driving differences in cost effectiveness of first-line pharmacological therapy for uncomplicated hypertension. Klarenbach SW, McAlister FA, Johansen H, Tu K, Hazel MA, Walker R, Zarnke KB, Campbell NRC, For the Canadian Hypertension Education Program, Can J Cardiol 2010 26 5 158 e163 10.1016/S0828-282X(10)70383-4 20485695
8. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 - therapy. Hackam DG, Khan NA, Hemmelgarn BR, Rakin SW, Touyz RM, Campbell NRC, Padwal R, Campbell TS, Lindsay PM, Hill MD, Quinn RR, Mahon JL, Herman RJ, Shiffrin EL, Ruzicka M, Larochelle P, Feldman RD, Lebel M, Poirier L, Arnold JMO, Moe GW, Howlett JG, Trudeau L, Bacon SL, Petrella RJ, Milot A, Stone JA, Drouin D, Boulanger JM, Sharma M, Hamet P, Fodor G, Dresser GK, Carruthers SG, Pylypchuk G, Burgess ED, Burns KD, Vallée M, Prasad Hamet P, Fodor G, Dresser GK, Carruthers SG, Pylypchuk G, Burgess ED, Burns KD, Vallée M, Prasad GV, Gilbert RE, Leiter LA, Jones C, Ogilvie RI, Woo V, McFarlane PA, Hegele RA, Tobe SW, Canadian Hypertension Education Program, Can J Cardiol 2010 26 5 249 258 10.1016/S0828-282X(10)70379-2 20485689
9. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ, National High Blood Pressure Education Program Coordinating Committee, JAMA 2003 289 2560 2572 10.1001/jama.289.19.2560 12748199 (Pubitemid 37430158)
10. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid Lowering Treatment to prevent Heart Attack Trial (ALLHAT). The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, JAMA 2002 288 2977 2981
11. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in elderly. Wing LMH, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GLR, Johnston CI, McNeil JJ, MacDonald GJ, Marley JE, Morgan TO, West MJ, For the Second Australian National Blood Pressure Study Group, N Engl J Med 2003 348 7 583 592 10.1056/NEJMoa021716 12584366 (Pubitemid 36204952)
12. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS, JAMA 2003 289 2534 2544 10.1001/jama.289.19.2534 12759325 (Pubitemid 37430155)
13. Cardiovascular prevention and blood pressure reduction: A quantitative overview updated until 1 March 2003. Staessen JA, Wang JG, Thijs L, J Hypertens 2003 21 6 1055 1076 10.1097/00004872-200306000-00002 12777939 (Pubitemid 36667856)
14. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Staessen JA, Li Y, Thijs L, Wang JG, Hypertens Res 2005 28 5 385 407 10.1291/hypres.28.385 16156503 (Pubitemid 41014801)
15. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lindholm LH, Carlberg B, Samuelsson O, Lancet 2005 366 1545 1553 10.1016/S0140-6736(05)67573-3 16257341 (Pubitemid 41540112)
16. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. Law MR, Morris JK, Wald NJ, BMJ 2009 338 1 19 10.1136/bmj.b1
17. Management of hypertension in adults in primary care. National Collaborating Centre for Chronic Conditions, NICE Clinical Guidelines 18 London: Royal College of Physicians 2006
18. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. Whitworth JA, J Hypertens 2003 21 11 1983 1992 14597836 (Pubitemid 38296854)
19. The potential economic impact of restricted access to angiotensin-receptor blockers. Guertin JR, Jackevicius CA, Cox JL, Humphries K, Pilote L, So DY, Tu JV, Wijeysundera H, Rinfret S, For the Canadian Cardiovascular Outcomes Research Team, CMAJ 2011 18 3 180 E186
20. Economic analysis of a randomized trial of academic detailing interventions to improve use of antihypertensive medications. Simon SR, Rodriguez HP, Majumdar SR, Kleinman K, Warner C, Salem-Schatz S, Miroshnik I, Soumerai SB, Prosser LA, J Clin Hypertens 2007 9 1 15 20 10.1111/j.1524-6175. 2006.05684.x
21. ASH Position Paper: adherence and persistence with taking medication to control high blood pressure. Hill MN, Miller NH, DeGeest S, On Behalf of the American Society of Hypertension Writing Group, J Clin Hypertens 2010 12 10 757 764 10.1111/j.1751-7176.2010.00356.x
22. Determinants of discontinuation of new courses of antihypertensive medications. Grégoire JP, Moisan J, Guibert R, Ciampi A, Milot A, Gaudet M, Côté I, J Clin Epidemiol 2002 55 7 728 735 10.1016/S0895- 4356(02)00400-6 12160922
23. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. Tamblyn R, Lavoie G, Petrella L, Monette J, J Clin Epidemiol 1995 48 8 999 1009 10.1016/0895-4356(94)00234-H 7775999
24. Influence of physicians' management and communication ability on patients' persistence with antihypertensive medication. Tamblyn R, Abrahamowicz M, Dauphinee D, Wenghofer E, Jacques A, Klass D, Smee S, Eguale T, Winslade N, Girard N, Bartman I, Buckeridge DL, Hanley JA, Arch Intern Med 2010 170 12 1064 1072 10.1001/archinternmed.2010.167 20585073
25. Are physicians with better clinical skills on licensing examinations less likely to prescribe antibiotics for viral respiratory infections in ambulatory care settings? Cadieux G, Abrahamowicz M, Dauphinee D, Tamblyn R, Med Care 2011 49 2 156 165 10.1097/MLR.0b013e3182028c1a 21206293
26. The Medical Office of the 21st century (MOXXI): effectiveness of computerized decision-making support in reducing inappropriate prescribing in primary care. Tamblyn R, Huang A, Perreault R, Jacques A, Roy D, Hanley J, McLeod P, Laprise R, CMAJ 2003 169 6 549 556 12975221 (Pubitemid 37174595)
27. The development and evaluation of an integrated electronic prescribing and drug management system for primary care. Tamblyn R, Huang A, Kawasumi Y, Bartlett G, Grad R, Jacques A, Dawes M, Abrahamowicz M, Perreault R, Taylor L, Winslade N, Poissant L, Pinsonneault A, J Am Med Inform Assoc 2006 13 2 148 159 10.1197/jamia.M1887 16357357 (Pubitemid 43332905)
28. Assessment of family physicians' performance using patient charts: Interrater reliability and concordance with chart-stimulated recall interview. Goulet F, Jacques A, Gagnon R, Racette P, Sieber W, Eval Health Prof 2007 30 4 376 392 10.1177/0163278707307924 17986671
29. Are physicians discussing prostate cancer screening with their patients and why or why not? A pilot study. Guerra CE, Jacobs SE, Holmes JH, Shea JA, J Gen Intern Med 2006 22 7 901 907 (Pubitemid 46878594)
30. Continuing medical education: Methods for both needs assessment and performance assessment. Mann KV, International handbook of research in medical education: Part one Netherlands: Kluwer Academic Publishers, Norman GR, van der Vleuten CPM, Newble DI, 2002 415 460
31. Determinants for the adoption of angiotensin II receptor blockers by general practitioners. Greving JP, Denig P, Jan van der Veen W, Beltman FW, Sturkenboom MCJM, Haaijer-Ruskamp FM, Soc Sci Med 2006 63 11 2890 2898 10.1016/j.socscimed.2006.07.019 16959390 (Pubitemid 44584502)
32. A qualitative study to explore influences on general practitioners' decisions to prescribe new drugs. Jacoby A, Smith M, Eccles M, Br J Gen Pract 2003 53 120 125 12817357 (Pubitemid 36187498)
33. New drug uptake: qualitative comparison of high and low prescribing GPs' attitudes and approach. Prosser H, Walley T, Fam Pract 2003 20 5 583 591 10.1093/fampra/cmg516 14507803 (Pubitemid 37258765)
34. Influences on GPs' decision to prescribe new drugs - the importance of who says what. Prosser H, Almond S, Walley T, Fam Pract 2003 20 1 61 68 10.1093/fampra/20.1.61 12509373 (Pubitemid 36163787)
35. Miles MB, Huberman M, Qualitative data analysis: an expanded source book Thousand Oaks: Sage 2 1994
36. Patton MQ, Qualitative research and evaluation methods Thousand Oaks: Sage 3 2001
37. An emerging strategy of direct research. Mintzberg H, Adm Sci Q 1979 24 582 589 10.2307/2392364
38. First-line drugs for hypertension. Wright JM, Musini VM, Cochrane Database of Syst Rev 2009 3 D001841
39. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Turnbull F, Blood Pressure Lowering Treatment Trialists' Collaboration, Lancet 2003 362 9395 1527 1535 14615107 (Pubitemid 37410190)
40. Misperceptions about beta-blockers and diuretics: a national survey of primary care physicians. Ubel PA, Jepson C, Asch DA, J Gen Intern Med 2003 18 12 977 983 10.1111/j.1525-1497.2003.20414.x 14687255 (Pubitemid 38091391)
41. Use of diuretics in patients with hypertension. Ernst ME, Moser M, N Engl J Med 2009 361 22 2153 2164 10.1056/NEJMra0907219 19940300
42. Why are physicians not prescribing diuretics more frequently in the management of hypertension? Moser M, JAMA 1998 279 22 1813 1816 10.1001/jama.279.22.1813 9628713 (Pubitemid 28280254)
43. Transforming trial results into practice change: the final translational hurdle: Comment on "Impact of the ALLHAT/JNC7 Dissemination Project on thiazide-type diuretic use". Avorn J, Arch Intern Med 2010 170 10 858 860 10.1001/archinternmed.2010.125 20498412
44. Diuretics for hypertension: an inconsistency in primary care prescribing behaviour. Kuehlein T, Laux G, Gutscher A, Goetz K, Szecsenyi J, Campbell S, Steinhaeuser J, Curr Med Res Opin 2011 27 3 497 502 10.1185/03007995.2010.547932 21208153
45. Achieving blood pressure goals: why aren't we? Cushman WC, Basile J, J Clin Hypertens 2006 8 12 865 872 10.1111/j.1524-6175.2006.05789.x
46. Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. Hyman DJ, Pavlik VN, Arch Intern Med 2000 160 15 2281 2286 10.1001/archinte.160.15.2281 10927724
47. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Sica DA, Drugs 2002 62 3 443 462 10.2165/00003495-200262030- 00003 11827559 (Pubitemid 34208333)
48. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Law MR, Wald NJ, Morris JK, Jordan RE, BMJ 2003 326 7404 1427 1431 10.1136/bmj.326.7404.1427 12829555 (Pubitemid 36776153)